Current Report · Items 8.01, 9.01 · 8-K
Apyx Medical Corporation
APYXNASDAQEQUITYCurrent
Other Events
Item Other 8.01. Events. On July 24, 2026, the Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) reconstituted the membership and chairs of its standing committees as described below. The membership and chairs of the reconstituted committees are as follows: Audit Committee: Lawrence J. Waldman (Chair), Minnie Baylor-Henry, and Wendy Levine; Governance and Nominating Committee:…
Recent company filings
- Other EventsSep 29, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersAug 7, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- SCHEDULE 13G/A - filed by ROYCE & ASSOCIATES LP regarding Apyx Medical CorpJul 21, 2026
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item Other
8.01. Events.
On
July 24, 2026, the Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) reconstituted
the membership and chairs of its standing committees as described below.
The
membership and chairs of the reconstituted committees are as follows:
Audit
Committee: Lawrence J. Waldman (Chair), Minnie Baylor-Henry, and Wendy Levine;
Governance
and Nominating Committee: Minnie Baylor-Henry (Chair), Lawrence J. Waldman, and Wendy
Levine;
Regulatory
Compliance Committee: Minnie Baylor-Henry (Chair), Lawrence J. Waldman, and Wendy Levine;
and
Compensation
Committee: Wendy Levine (Chair), Lawrence J. Waldman, and Minnie Baylor-Henry.
In
light of his appointment as Executive Chairman of the Board (effective June 11, 2026), Stavros Vizirgianakis will not serve on any committee
of the Board.
The
Board has determined that each of Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine is “independent” under the applicable rules
of The Nasdaq Global Select Market and the Securities and Exchange Commission. The Board has further determined that Mr. Waldman qualifies
as an “audit committee financial expert” as defined by the rules and regulations of the Securities and Exchange Commission.